HLA-B Antigens (HLA-B)

Class I human histocompatibility (HLA) surface antigens encoded by more than 30 detectable alleles on locus B of the HLA complex, the most polymorphic of all the HLA specificities. Several of these antigens (e.g., HLA-B27, -B7, -B8) are strongly associated with predisposition to rheumatoid and other autoimmune disorders. Like other class I HLA determinants, they are involved in the cellular immune reactivity of cytolytic T lymphocytes.

Also Known As:

Networked: 1076 relevant articles (20 outcomes, 129 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Carrington, Mary: 20 articles (06/2014 - 08/2002)
2.	Mallal, Simon: 18 articles (01/2015 - 03/2004)
3.	Walker, Bruce D: 18 articles (12/2014 - 12/2004)
4.	Pirmohamed, Munir: 13 articles (08/2015 - 06/2004)
5.	Brander, Christian: 12 articles (11/2015 - 12/2004)
6.	Hung, Shuen-Iu: 11 articles (12/2015 - 04/2004)
7.	Oka, Shinichi: 11 articles (07/2015 - 01/2005)
8.	Takiguchi, Masafumi: 11 articles (07/2015 - 01/2005)
9.	Goulder, Philip J R: 11 articles (12/2014 - 12/2004)
10.	Chung, Wen-Hung: 10 articles (12/2015 - 04/2004)

Related Diseases

1.	Hypersensitivity (Allergy) 02/01/2011 - "To determine the frequencies of HLA-B alleles in Ugandan patients in the NORA substudy of the DART trial and to compare HLA-B allele frequencies in those with and without clinically diagnosed hypersensitivity reaction (HSR). " 04/01/2008 - "This paper outlines the design of a study to evaluate the utility of prospective screening for HLA-B*5701 to reduce the incidence of ABC hypersensitivity in an ABC-naïve population of HIV-infected subjects. " 01/01/2014 - "HLA-B allele and haplotype diversity among Thai patients identified by PCR-SSOP: evidence for high risk of drug-induced hypersensitivity." 12/01/2013 - "Suspected hypersensitivity reactions were the main cause of discontinuation due to intolerance (27.6%); the rate was 3.8% when ABC had been introduced before the routine use of the screening test HLA-B*5701. " 09/01/2013 - "This patient had no previous food or medication allergy history and presented a negative test result of HLA-B*1502 genotype. "
2.	Ankylosing Spondylitis 12/01/2013 - "The aim of this study was to assess the role of HLA-B*27 and it's subtypes in determining severity and clinical manifestations of ankylosing spondylitis (AS).A total of 163 AS patients were assessed for clinical manifestations and severity using structured questionnaires. " 01/01/2013 - "Profiling of hla-B alleles for association studies with ankylosing spondylitis in the chinese population." 04/01/2011 - "A polymerase chain reaction with specific sequence primer method were used to study the HLA-B* locus polymorphism in 50 Syrian patients fulfilling the modified New York criteria for classification of ankylosing spondylitis and 217 unrelated healthy Syrian controls. " 03/01/2011 - "The aim of this study was to determine whether the HLA-B*27 polymorphisms confer susceptibility to ankylosing spondylitis (AS) in Han populations by conducting a meta-analysis. " 04/01/2015 - "The human MHC class I protein HLA-B*27:05 is statistically associated with ankylosing spondylitis, unlike HLA-B*27:09, which differs in a single amino acid in the F pocket of the peptide-binding groove. "
3.	Cicatrix (Scar) 10/01/2015 - "Compared with the previous retrospective cohort study, a significant reduction in SCARs was observed in HLA-B*58:01-positive patients (0 vs. 18%; P = 0.002). " 04/01/2015 - "The aim of our study was to determine the frequency of HLA-B(*)1502 in SCARs patients at a large University Medical Center in Hanoi, Vietnam. " 04/01/2015 - "In other Asian countries, HLA-B(*)1502 is an established risk factor for SCARs. " 05/01/2013 - "There was no association between the HLA-B*1502 and aromatic anticonvulsant-induced severe cutaneous adverse reactions (SCARs). " 01/01/2015 - "Prospective screening of the HLA-B*58:01 allele, coupled with an alternative drug treatment for carriers, significantly decreased the incidence of allopurinol induced SCARs in Taiwanese medical centres."
4.	Disease Progression 09/10/2011 - "The fact that such adaptations are driven by the HLA-B molecules that provide best protection against HIV-1 disease progression has important implications for our understanding of HIV evolution." 01/01/2016 - "HLA-B*46 was not associated with disease progression. " 01/01/2016 - "We hypothesized that alleles predicted to confer more effective immune responses, such as HLA-B*46, would protect against disease progression. " 07/01/2015 - "We sought to determine the role of HLA-B allele frequency on rapid HIV disease progression. " 09/01/2014 - "The observed lower replication rate in HLA-B*5701 subjects with higher baseline CD4+ T cell counts provides a potential model to explain differences in risk of disease progression among individuals carrying this allele. "
5.	Infection 01/01/2013 - "The risk profile of polymorphisms at position 97 of HLA-B are more broadly associated with HIV-1 viral load during primary infection and may serve as a focal point in further studies of HLA-B function." 01/01/2013 - "This study sought to determine the role of HLA-B alleles in viral control during the acute phase of HIV-1 infection and establishment of the early viral load set point (VLSP). " 09/01/2012 - "The present study investigated HIV-1 in vivo evolution and epitope-specific CD8(+) T cell responses in six HLA-B*5701 patients who had not received antiretroviral treatment, monitored from early infection for up to 7 years. " 08/01/2012 - "The aims of this study were to evaluate the variants in HLA-B associated transcript 2 (BAT2), CXCL12, myxovirus resistance protein 1 (Mx1) and EHMT2 genes and their effects on the risk of infection PRRSV and H. " 10/01/2009 - "In this study of pediatric infection, we tested the hypothesis that children may tend to progress relatively slowly if either they themselves possess one of the protective HLA-B alleles or the mother possesses one of these alleles, thereby transmitting a low-fitness virus to the child. "

Related Drugs and Biologics

1.	abacavir (Ziagen)
2.	HLA-A Antigens (HLA-A)
3.	HLA-C Antigens (HLA-C)
4.	Antigens
5.	HLA-DRB1 antigen (HLA DRB1)
6.	HLA-DQB1 antigen (HLA DQB1)
7.	mica
8.	Allopurinol (Remid)
9.	HLA-B27 Antigen (HLA B27 Antigen)
10.	Epitopes

Related Therapies and Procedures

1.	Transplants (Transplant)
2.	Transplantation (Transplant Recipients)
3.	Highly Active Antiretroviral Therapy (HAART)
4.	Homologous Transplantation (Allograft)
5.	Immunotherapy